Description: <b>Anamu</b> (Guinea Hen Weed) Anamu (Petiveria alliacea)<br>
A herb that is indigenous to the Amazon rainforest and the tropical areas of the Caribbean, Central and South America and Africa. <br>
Anamu has been used for a wide variety of conditions, including arthritis, digestive disorders, infections, diabetes, cancer, for pain relief, and to induce abortion.<br>
<p><b>Anamu</b> — Anamu is the medicinal plant <i>Petiveria alliacea</i>, also called Guinea hen weed, with dibenzyl trisulfide as a prominent organosulfur bioactive linked to anticancer mechanistic work. It is best classified as a botanical extract / organosulfur natural-product source rather than a single defined drug, because published studies use crude extracts, standardized fractions, and isolated dibenzyl trisulfide. The plant is native or naturalized across tropical South and Central America, the Caribbean, parts of Africa, and the southeastern United States. Translational relevance is limited by heterogeneous extract chemistry, sparse human efficacy data, and potential reproductive, genotoxic, and hepatic safety constraints.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Direct cytotoxic stress in cancer cells through lysosomal membrane permeabilization and caspase-independent cell death, especially shown for isolated DTS in triple-negative breast cancer models.</li>
<li>Suppression of proliferative kinase signaling, including reported RSK1 inhibition by DTS and context-dependent MAPK axis modulation.</li>
<li>Metabolic suppression in leukemia and tumor-cell models, including ↓ glucose uptake, ↓ oxygen consumption, ↓ intracellular ATP, and altered glycolytic / oxidative phosphorylation metabolites.</li>
<li>ROS-linked antiproliferative stress, with ROS increase reported in some leukemia models; this appears secondary/context-dependent rather than a universal primary axis.</li>
<li>Migration and metastasis suppression in preclinical models, linked to reduced tumor burden, reduced blast infiltration, and immune-response modulation in murine leukemia work.</li>
<li>Immune / cytokine modulation, including older reports of Th1/Th2 cytokine switching, but this is not yet a validated oncology clinical mechanism.</li>
<li>Chemoprevention-like CYP1A inhibition by DTS, which may reduce activation of some environmental procarcinogens but is distinct from direct tumor killing.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Human PK for Anamu extracts or isolated DTS is not well established. Oral use is common in supplements and teas, but standardized exposure, active-metabolite formation, tissue distribution, and dose-response relationships are poorly defined. Extract identity is critical because water, ethanol, and fractionated preparations are not interchangeable.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Most anticancer evidence is in vitro or murine, and common cell-culture concentrations may not map to achievable human plasma or tumor exposure. For crude extracts, concentration equivalence is especially weak because active DTS and other sulfur constituents vary by plant part, extraction method, and storage.</p>
<p><b>Clinical evidence status:</b> Preclinical dominant. One registered phase Ib/II protocol is evaluating standardized Anamu extract as an adjunct with conventional therapy in metastatic gastrointestinal tumors and acute leukemias, but efficacy is not established. MSKCC states that <i>Petiveria alliacea</i> has not been shown to treat cancer in humans. A small osteoarthritis trial did not show benefit over placebo.</p>
<h3>Anamu Mechanistic Profile</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Lysosomal membrane permeabilization</td>
<td>↑ lysosomal destabilization; ↑ cathepsin-linked stress; ↑ caspase-independent death</td>
<td>Unknown selectivity; normal-cell cytotoxicity not adequately resolved</td>
<td>G</td>
<td>Cell death induction</td>
<td>Strongest modern isolated-DTS mechanism; most relevant where apoptosis resistance limits therapy response.</td>
</tr>
<tr>
<td>2</td>
<td>RSK1 and MAPK signaling</td>
<td>↓ RSK1 activity; MAPK modulation context-dependent</td>
<td>Potential signaling effects unclear</td>
<td>R/G</td>
<td>Proliferation signaling disruption</td>
<td>DTS literature emphasizes kinase inhibition or ERK/MAPK suppression; direction should be treated as context-dependent.</td>
</tr>
<tr>
<td>3</td>
<td>Glycolysis and oxidative phosphorylation</td>
<td>↓ glucose uptake; ↓ OCR; ↓ ATP; ↓ proliferative metabolites</td>
<td>Unknown; potential energy-metabolism liability in high-demand normal tissues not defined</td>
<td>G</td>
<td>Metabolic growth constraint</td>
<td>Important for leukemia models and drug-resistant tumor metabolism, but extract-specific and not yet PK-linked.</td>
</tr>
<tr>
<td>4</td>
<td>ROS increase secondary</td>
<td>↑ ROS in some leukemia models; antiproliferative stress</td>
<td>Possible oxidative stress at high or poorly standardized exposure</td>
<td>R/G</td>
<td>Stress amplification</td>
<td>ROS appears mechanistically relevant but not universal; avoid assuming NRF2 direction without model-specific data.</td>
</tr>
<tr>
<td>5</td>
<td>NRF2 antioxidant response</td>
<td>↔ insufficient direct evidence for consistent modulation</td>
<td>↔ insufficient direct evidence</td>
<td>G</td>
<td>Uncertain stress-response adaptation</td>
<td>Do not list as a core Anamu mechanism unless a specific study reports NRF2 or downstream antioxidant targets.</td>
</tr>
<tr>
<td>6</td>
<td>Migration and metastasis programs</td>
<td>↓ migration; ↓ metastasis-related behavior; ↓ tumor burden in murine AML model</td>
<td>Unknown</td>
<td>G</td>
<td>Invasion suppression</td>
<td>Preclinical evidence supports antimetastatic potential, but clinical relevance remains unproven.</td>
</tr>
<tr>
<td>7</td>
<td>Immune and cytokine balance</td>
<td>↓ immunosuppressive tumor burden signals in murine leukemia context</td>
<td>↑ or ↔ cytokine modulation; Th1/Th2 shift reported historically</td>
<td>G</td>
<td>Host immune modulation</td>
<td>Potential adjunctive axis; not sufficiently validated for clinical cancer use.</td>
</tr>
<tr>
<td>8</td>
<td>CYP1A carcinogen activation</td>
<td>↓ CYP1A-mediated procarcinogen activation potential</td>
<td>↓ CYP1A activity possible</td>
<td>R/G</td>
<td>Chemoprevention-like enzyme inhibition</td>
<td>DTS was reported as a direct reversible competitive CYP1A inhibitor; this is more relevant to carcinogen activation than treatment of established tumors.</td>
</tr>
<tr>
<td>9</td>
<td>Cell cycle arrest</td>
<td>↑ growth arrest; ↓ proliferation</td>
<td>Unknown</td>
<td>G</td>
<td>Antiproliferative effect</td>
<td>Likely downstream of metabolic and kinase stress rather than an independent primary mechanism.</td>
</tr>
<tr>
<td>10</td>
<td>Clinical Translation Constraint</td>
<td>Extract heterogeneity; limited human cancer efficacy data; uncertain achievable exposure</td>
<td>Pregnancy concern; genotoxicity signals; possible liver injury; supplement quality variability</td>
<td>G</td>
<td>Limits clinical deployment</td>
<td>Not an approved oncology drug; standardized clinical extract data should not be generalized to all commercial Anamu products.</td>
</tr>
</tbody>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>